Home World News FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma World News FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 670 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... September 21, 2021 EMA Recommends Extension of Indications for Selumetinib October 9, 2025 No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... March 24, 2025 Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... January 27, 2025 Load more HOT NEWS Foodie Fridays: Watermelon Salad Holiday Lights Are My Favorite Thing PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening...
